Propranolol
- Generic Name
- Propranolol
- Brand Names
- Hemangeol, Hemangiol, Inderal, Innopran
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21NO2
- CAS Number
- 525-66-6
- Unique Ingredient Identifier
- 9Y8NXQ24VQ
- Background
Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors. Propranolol is used to treat a number of conditions but most commonly is used for hypertension.
Propranolol was granted FDA approval on 13 November 1967.
- Indication
Propranolol is indicated to treat hypertension. Propranolol is also indicated to treat angina pectoris due to coronary atherosclerosis, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, pheochromocytoma, and proliferating infantile hemangioma.
- Associated Conditions
- Akathisia caused by antipsychotic use, Angina Pectoris, Atrial Fibrillation, Cardiovascular Mortality, Essential Tremor, Gastroesophageal variceal hemorrhage prophylaxis, Hemangiomas, Hypertension, Migraine, Myocardial Infarction, Obstructive Hypertrophic Cardiomyopathy, Performance Anxiety, Pheochromocytoma, Proliferating Infantile Hemangioma, Supraventricular Arrhythmias, Tachyarrhythmia caused by Digitalis intoxication, Tachyarrhythmia caused by catecholamine excess, Thyroid Crisis, Thyrotoxicosis, Tremor caused by lithium, Ventricular Tachycardia (VT)
- Associated Therapies
- -
Protective Effects of Propranolol in Adults
- First Posted Date
- 2013-07-18
- Last Posted Date
- 2019-11-29
- Target Recruit Count
- 47
- Registration Number
- NCT01902810
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸Cornell Burn Center, New York, New York, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
PROPRANOLOL PLUS LIGATION REDUCES RECURRENCE OF ESOPHAGEAL VARICES?
- Conditions
- Interventions
- First Posted Date
- 2013-07-09
- Last Posted Date
- 2013-07-09
- Lead Sponsor
- Federal University of São Paulo
- Target Recruit Count
- 100
- Registration Number
- NCT01893541
- Locations
- 🇧🇷
Federal University of São Paulo, São Paulo, Brazil
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2013-05-06
- Last Posted Date
- 2021-09-10
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 10
- Registration Number
- NCT01847001
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Efficacy of Clonidine and Propranolol in Dentistry (AAA)
- First Posted Date
- 2013-02-05
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- CES University
- Target Recruit Count
- 60
- Registration Number
- NCT01784250
- Locations
- 🇨🇴
Cooperative University, Envigado, Antioquia, Colombia
Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2016-06-01
- Lead Sponsor
- University Hospital, Montpellier
- Target Recruit Count
- 55
- Registration Number
- NCT01743885
- Locations
- 🇫🇷
Chirurgy Plastic Department, Montpellier, France
🇫🇷UH Lyon, Lyon, France
🇫🇷UH NCaremeau, Nîmes, France
Treatment of PTSD by Reduction of Traumatic Memory Reconsolidation by Propranolol : a Multisite Trial
- Conditions
- Interventions
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 87
- Registration Number
- NCT01713556
- Locations
- 🇫🇷
Chu Montpellier, Montpellier, France
🇫🇷Centre Hospitalier Charles Perrens, Bordeaux, France
🇫🇷Chru Lille, Lille, France
Bevacizumab vs Dacarbazine in Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Haukeland University Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT01705392
- Locations
- 🇳🇴
Haukeland University Hospital, Bergen, Norway
Rate Control in Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2012-08-01
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 90
- Registration Number
- NCT01655303
- Locations
- 🇮🇷
Rasoul-e-Akram Hospital, Tehran, Iran, Islamic Republic of
Pilot Study of Pharmaceutical and Behavioral Interventions to Treat Anxiety Disorders
- Conditions
- Interventions
- First Posted Date
- 2012-06-29
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 186
- Registration Number
- NCT01631682
- Locations
- 🇺🇸
Massachusetts General Hospital, Charlestown, Massachusetts, United States
Beta Blocker Therapy in Mild to Moderate Asthmatics
- Conditions
- Interventions
- First Posted Date
- 2012-03-06
- Last Posted Date
- 2018-03-30
- Lead Sponsor
- University of Dundee
- Target Recruit Count
- 16
- Registration Number
- NCT01544634
- Locations
- 🇬🇧
Asthma and Allergy Research Group, University of Dundee, Dundee, Scotland, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.